Influence of CD4+CD25+ regulatory T cells on low/high-avidity CD4+ T cells following peptide vaccination
- PMID: 16670346
- DOI: 10.4049/jimmunol.176.10.6340
Influence of CD4+CD25+ regulatory T cells on low/high-avidity CD4+ T cells following peptide vaccination
Abstract
We have recently reported that NY-ESO-1-specific naive CD4+ T cell precursors exist in most individuals but are suppressed by CD4+CD25+ regulatory T cells (Tregs), while memory CD4+ T cell effectors against NY-ESO-1 are found only in cancer patients with spontaneous Ab responses to NY-ESO-1. In this study, we have analyzed mechanisms of CD4+ T cell induction following peptide vaccination in relation to susceptibility to Tregs. Specific HLA-DP4-restricted CD4+ T cell responses were elicited after vaccination with NY-ESO-1(157-170) peptide (emulsified in IFA) in patients with NY-ESO-1-expressing epithelial ovarian cancer. These vaccine-induced CD4+ T cells were detectable from effector/memory populations without requirement for in vitro CD4+CD25+ T cell depletion. However, they were only able to recognize NY-ESO-1(157-170) peptide but not naturally processed NY-ESO-1 protein and had much lower avidity compared with NY-ESO-1-specific pre-existing naive CD4+CD25- T cell precursors or spontaneously induced CD4+ T cell effectors of cancer patients with NY-ESO-1 Ab. We propose that vaccination with NY-ESO-1(157-170) peptide recruits low-avidity T cells with low sensitivity to Tregs and fails to modulate the suppressive effect of Tregs on high-avidity NY-ESO-1-specific T cell precursors.
Similar articles
-
Induction of regulatory T cell-resistant helper CD4+ T cells by bacterial vector.Blood. 2008 Feb 1;111(3):1404-12. doi: 10.1182/blood-2007-09-113761. Epub 2007 Nov 6. Blood. 2008. PMID: 17986662
-
HLA-DP4 expression and immunity to NY-ESO-1: correlation and characterization of cytotoxic CD4+ CD25- CD8- T cell clones.Cancer Immun. 2004 Dec 16;4:15. Cancer Immun. 2004. PMID: 15600300
-
One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma.J Immunol. 2005 Feb 1;174(3):1751-9. doi: 10.4049/jimmunol.174.3.1751. J Immunol. 2005. PMID: 15661941
-
Production of NY-ESO-1 peptide/DRB1*08:03 tetramers and ex vivo detection of CD4 T-cell responses in vaccinated cancer patients.Vaccine. 2014 Feb 12;32(8):957-64. doi: 10.1016/j.vaccine.2013.12.042. Epub 2014 Jan 5. Vaccine. 2014. PMID: 24397899
-
T-Regulatory Cells and Vaccination "Pay Attention and Do Not Neglect Them": Lessons from HIV and Cancer Vaccine Trials.Vaccines (Basel). 2016 Sep 5;4(3):30. doi: 10.3390/vaccines4030030. Vaccines (Basel). 2016. PMID: 27608046 Free PMC article. Review.
Cited by
-
FOXP3+ Tregs: heterogeneous phenotypes and conflicting impacts on survival outcomes in patients with colorectal cancer.Immunol Res. 2015 Mar;61(3):338-47. doi: 10.1007/s12026-014-8616-y. Immunol Res. 2015. PMID: 25608795 Review.
-
NY-ESO-1 DNA vaccine induces T-cell responses that are suppressed by regulatory T cells.Clin Cancer Res. 2009 Mar 15;15(6):2130-9. doi: 10.1158/1078-0432.CCR-08-2632. Epub 2009 Mar 10. Clin Cancer Res. 2009. PMID: 19276258 Free PMC article. Clinical Trial.
-
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans.Proc Natl Acad Sci U S A. 2013 Oct 29;110(44):17945-50. doi: 10.1073/pnas.1316796110. Epub 2013 Oct 14. Proc Natl Acad Sci U S A. 2013. PMID: 24127572 Free PMC article.
-
NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer.Gynecol Oncol. 2017 Jun;145(3):420-425. doi: 10.1016/j.ygyno.2017.03.509. Epub 2017 Apr 6. Gynecol Oncol. 2017. PMID: 28392127 Free PMC article.
-
Mobilizing the low-avidity T cell repertoire to kill tumors.Semin Cancer Biol. 2007 Aug;17(4):317-29. doi: 10.1016/j.semcancer.2007.06.006. Epub 2007 Jun 23. Semin Cancer Biol. 2007. PMID: 17651986 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials